As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
This article was originally published in PharmAsia News
MUMBAI - India's vaccines specialist Bharat Biotech is reshaping prices of life-saving vaccines with the announcement that it will make available its rotavirus vaccine at $1 per dose for government supplies once it clears Phase III trials. Bharat Biotech expects the product to be market-ready in the next three years
You may also be interested in...
Davinder Gill provides an update on the sharpened focus of the New Delhi-based MSD-Wellcome Trust Hilleman Laboratories as it seeks to narrow its research and development focus in developing vaccines for low-income emerging markets.
Pushed by an expanded immunization program and a steady flow of new generation vaccines, India’s vaccine industry could grow to $1.65 billion if projected scenarios unfold.
Serum Institute Of India Chairman Cyrus Poonawalla On How To Succeed In The Vaccines Business: An Interview With PharmAsia News
In a rare interview, Serum Institute of India Chairman Cyrus Poonawalla discusses his determination to keep vaccine prices low for India’s masses and his ongoing battles with multinational pharma companies.